Recent and anticipated novel drug approvals (1Q 2026 through 4Q 2026) | American Journal of Health-System Pharmacy
• The American Journal of Health-System Pharmacy has outlined the pharmaceutical pipeline for novel drug approvals anticipated between 1Q 2026 and 4Q 2026. • The upcoming pipeline focuses on therapies for rare inherited genetic disorders, immunologic and inflammatory diseases, and advancements in gene therapy and targeted oncology. • This tracking is critical for health-system pharmacists to effectively manage hospital formularies, allocate financial resources, and optimize patient care.
doi.org